318 related articles for article (PubMed ID: 17405908)
1. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.
Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A
Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908
[TBL] [Abstract][Full Text] [Related]
2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response.
Ward J; Davis Z; DeHart J; Zimmerman E; Bosque A; Brunetta E; Mavilio D; Planelles V; Barker E
PLoS Pathog; 2009 Oct; 5(10):e1000613. PubMed ID: 19798433
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
6. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
[TBL] [Abstract][Full Text] [Related]
7. Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression.
Pignoloni B; Fionda C; Dell'Oste V; Luganini A; Cippitelli M; Zingoni A; Landolfo S; Gribaudo G; Santoni A; Cerboni C
J Immunol; 2016 Nov; 197(10):4066-4078. PubMed ID: 27733551
[TBL] [Abstract][Full Text] [Related]
8. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
[TBL] [Abstract][Full Text] [Related]
9. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
10. Proteasome regulation of ULBP1 transcription.
Butler JE; Moore MB; Presnell SR; Chan HW; Chalupny NJ; Lutz CT
J Immunol; 2009 May; 182(10):6600-9. PubMed ID: 19414815
[TBL] [Abstract][Full Text] [Related]
11. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
12. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
[TBL] [Abstract][Full Text] [Related]
13. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.
Richard J; Sindhu S; Pham TN; Belzile JP; Cohen EA
Blood; 2010 Feb; 115(7):1354-63. PubMed ID: 20008788
[TBL] [Abstract][Full Text] [Related]
15. A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner.
Bálint Š; Lopes FB; Davis DM
Sci Signal; 2018 Apr; 11(525):. PubMed ID: 29636390
[TBL] [Abstract][Full Text] [Related]
16.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
17. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
18. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
19. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
20. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
